Zogenix (ZGNX), Battelle Finalize DosePro Licensing, Development Opportunities

Zogenix, Inc. (Nasdaq: ZGNX) and Battelle have finalized their previously announced collaborative agreement to advance out-licensing opportunities and development of Zogenix's DosePro drug delivery technology. Battelle and Zogenix will co-market DosePro technology to potential pharmaceutical and government clients with the objective of licensing the system for use with innovative therapeutics that would be enabled or enhanced by DosePro's unique needle-free delivery system.

DosePro offers increased safety and convenience compared to needle-based injection via syringes or auto-injectors by providing a pre-filled, single-use, disposable, needle-free drug delivery system that is easy to use and preferred by patients. Compared to other delivery technologies, DosePro has the potential to solve the significant challenges of delivering viscous drug formulations, such as high concentration biologics, which cannot be delivered with traditional needle-based injection.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Real and RE/MAX Holdings receive court approval for merger
• loanDepot receives NYSE non-compliance notice over stock price